Non-Toxic Therapeutic Strategies for Treatment of Pediatric Brain Cancers

Technology #d-1000

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
Kalkunte Srivenugopal
Kalkunte S. Srivenugopal, PhD (Venu) is a tenured Professor in the Department of Biomedical Sciences at Texas Tech University Health Sciences Center School of Pharmacy.
External Link (www.ttuhsc.edu)
Managed By
David McClure
Director Licensing 806-834-5899
Patent Protection

Provisional Patent Application Filed

PCT Patent Application Filed
Files and Attachments
Carcinogenesis-2014-Paranjpe-692-702.pdf [PDF]

MGMT is a DNA repair protein that interferes with the cytotoxic action of alkylating chemotherapy agents.  Because of the prevalence of this protein in tumors, especially brain tumors, there is a great need for the discovery of an inhibitor that will not harm bone marrow stem cells.  This invention has solved this problem through the discovery of a novel use for an existing FDA approved drug used for the treatment of alcoholism, disulfiram.


Market Applications:

• Cancer Therapeutics


Features, Benefits, and Advantages:

The alcohol aversion drug disulfiram (DSF) reacts and conjugates with the protein-bound nucleophilic cysteines and is known to elicit anticancer effects alone or improve the efficacy of many cancer drugs.  This invention investigated the effects of disulfiram on human MGMT, a DNA repair protein and chemotherapy target that removes the mutagenic O6-akyl groups from guanines, and thus confers resistance to alkylating agents in brain tumors.  Treatment with DSF inhibited the MGMT activity in two brain tumor cell lines in a rapid and dose-dependent manner.  DSF was a weaker inhibitor of MGMT, compared to the established O6-benzylguanine, nevertheless, the 24-36 h suppression of MGMT activity in cell cultures vastly increased the alkylation-induced DNA interstrand crosslinking, G2/M cell cycle blockade, cytotoxicity, and the levels of apoptotic markers.

• Increased efficacy of cancer treatment

• Decreased side-effects, as compared to existing MGMT inhibitors


Development Stage:

This technology has been produced and tested.